Fortrea Holdings Inc.FTREEarnings & Financial Report
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
FTRE Q3 2025 Key Financial Metrics
Revenue
$701.3M
Gross Profit
N/A
Operating Profit
$-8.6M
Net Profit
$-15.9M
Gross Margin
N/A
Operating Margin
-1.2%
Net Margin
-2.3%
YoY Growth
3.9%
EPS
$-0.17
Financial Flow
Fortrea Holdings Inc. Q3 2025 Financial Summary
Fortrea Holdings Inc. reported revenue of $701.3M for Q3 2025, with a net profit of $-15.9M (-2.3% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $701.3M |
|---|---|
| Net Profit | $-15.9M |
| Gross Margin | N/A |
| Operating Margin | -1.2% |
| Report Period | Q3 2025 |
Fortrea Holdings Inc. Annual Revenue by Year
Fortrea Holdings Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.7B).
| Year | Annual Revenue |
|---|---|
| 2024 | $2.7B |
| 2023 | $3.1B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $845.7M | $662.1M | $662.4M | $674.9M | $697.0M | $651.3M | $710.3M | $701.3M |
| YoY Growth | N/A | -4.6% | -16.5% | -13.1% | -17.6% | -1.6% | 7.2% | 3.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $4.36B | $4.24B | $3.57B | $3.66B | $3.58B | $3.12B | $2.84B | $2.74B |
| Liabilities | $2.62B | $2.65B | $2.10B | $2.15B | $2.22B | $2.26B | $2.25B | $2.16B |
| Equity | $1.74B | $1.59B | $1.46B | $1.51B | $1.36B | $858.8M | $589.2M | $580.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-25.6M | $273.7M | $-2.4M | $17.1M | $-124.2M | $21.8M | $86.8M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M